对晚期肝细胞癌的-90放射栓塞的概述:目前的状况和未来的前景
Zong-Yang Li1, Cheng Xie1, Hong-Qiao Cai2
1Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
World journal of clinical oncology
|September 30, 2025
概括
放射栓塞为晚期肝细胞癌 (HCC) 提供了向治疗,显示出与全身疗法相比的有希望的结果. 这种地方区域的方法改善了疾病控制,并可以帮助HCC患者获得移植资格.
科学领域:
- 肝胆瘤学 肝胆瘤学
- 干预性放射学是干预性的放射学.
- 核医学是一种核医学.
背景情况:
- 肝细胞癌 (HCC) 是癌症死亡的主要原因,通常在晚期被诊断出来.
- 治愈性治疗对于中期或晚期HCC患者来说,往往不是一种选择.
- 地方区域疗法对于管理先进的HCC至关重要.
研究的目的:
- 为高级HCC.提供放射性栓塞的全面概述.
- 讨论放射栓塞的机制,技术方面和临床有效性.
- 突出放射性栓塞在当前和未来HCC管理中的作用.
主要方法:
- 对具有里程碑意义的临床试验进行审查 (SARAH,SIRveNIB,DOSISPHERE-01).
- 使用-90微球分析放射性栓塞的机制.
- 讨论技术考虑,包括个性化剂量计.
主要成果:
- 放射性栓塞证明了与 sorafenib 等全身疗法相比或优于其结果.
- 个性化剂量计提高了放射性栓塞的疗效.
- 该疗法有助于减缓瘤的发展阶段,移植桥梁和疾病控制.
结论:
- 放射栓塞是晚期HCC的一个有价值的选择,特别是在门静脉瘤血栓形成或肝功能受损的情况下.
- 与全身疗法的整合是一个有前途的研究方向.
- 在成像,同位素和个性化策略方面的创新将进一步完善放射栓塞在HCC管理中的作用.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K